Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) EBITDA Margin (2021 - 2025)

Verrica Pharmaceuticals has reported EBITDA Margin over the past 5 years, most recently at 141.24% for Q4 2025.

  • Quarterly results put EBITDA Margin at 141.24% for Q4 2025, up 317562.0% from a year ago — trailing twelve months through Dec 2025 was 34.25% (up 55812.0% YoY), and the annual figure for FY2025 was 34.25%, up 83700.0%.
  • EBITDA Margin for Q4 2025 was 141.24% at Verrica Pharmaceuticals, down from 11.34% in the prior quarter.
  • Over the last five years, EBITDA Margin for VRCA hit a ceiling of 11.89% in Q2 2025 and a floor of 17808.11% in Q1 2023.
  • Median EBITDA Margin over the past 5 years was 850.26% (2023), compared with a mean of 2762.41%.
  • Biggest five-year swings in EBITDA Margin: tumbled -1583525bps in 2023 and later skyrocketed 1732199bps in 2024.
  • Verrica Pharmaceuticals' EBITDA Margin stood at 7.78% in 2021, then tumbled by -111432bps to 8680.88% in 2022, then surged by 86bps to 1238.13% in 2023, then plummeted by -168bps to 3316.86% in 2024, then skyrocketed by 96bps to 141.24% in 2025.
  • The last three reported values for EBITDA Margin were 141.24% (Q4 2025), 11.34% (Q3 2025), and 11.89% (Q2 2025) per Business Quant data.